Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03379532 · ClinicalTrials.gov registry record · NA
BCI-controlled NMES in Subacute Stroke
A NA study of Stroke, sponsored by University Hospital, Geneva.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
- 2
- Study locations
NCT03379532: Completed NA study of Stroke, sponsored by University Hospital, Geneva.
NCT03379532 is a NA study of Stroke that has completed, run by University Hospital, Geneva. The registered enrollment target is 31 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03379532, a NA study of Stroke, has completed, sponsored by University Hospital, Geneva.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
- 2
- Study locations
Study Summary
Stroke patients with severe upper limb movement deficits have limited treatment options and often remain severely handicapped at the chronic stage. Recent findings have suggested that poor motor recovery can be due to severe damage of the cortico-spinal tract (CST), the neural fibres connecting the movement regions of the brain to the spinal cord. Hence, to improve recovery of upper limb movements it will be crucial to re-establish and strengthen CST projections. Recent studies provided evidence that closed-loop brain computer interface-driven electrical stimulation of the paretic muscles can induce clinically important and lasting recovery of upper limb function, even in patients with chronic, severe motor affection. In this treatment approach, movement intentions of the patients are detected with electroencephalography and real-time analyses. This triggers an electrical stimulation of affected upper limb muscles. In this study, the investigators hypothesize that neuromuscular electrical stimulation (NMES) applied contingent to voluntary activation of primary motor cortex, as detected by a brain-computer interface (BCI), can help restore CST projections. This might improve recovery of patients with severe upper limb movement deficits. Treatment will be started within the first 8 weeks after stroke onset.
Primary Outcome
Scale 0-66, higher scores indicate better outcome
Conditions Studied
Interventions
- DEVICE BCI-NMES
- DEVICE Sham-NMES
Study Locations (2)
Texas
- University of Austin - Austin
Canton of Geneva
- Division of Neurorehabilitation, University Hospital of Geneva - Geneva
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2018-01-26 |
| Est. Completion | 2024-04-30 |
| Phase | NA |
What the finished NCT03379532 record still lists
NCT03379532 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Stroke appearing as the primary indexed condition, and to 2 interventions - of which BCI-NMES is the first listed.
NCT03379532 reports a single indexed study location in Texas, Canton of Geneva.
Frequently Asked Questions
What is clinical trial NCT03379532 about?
NCT03379532 is a clinical study titled "BCI-controlled NMES in Subacute Stroke". Stroke patients with severe upper limb movement deficits have limited treatment options and often remain severely handicapped at the chronic stage. Recent findings have suggested that poor motor recovery can be due to severe damage of the cortico-spinal tract (CST), the neural fibres connecting the...
What is the current status of trial NCT03379532?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2018-01-26. Estimated completion is 2024-04-30.
What conditions does trial NCT03379532 study?
This clinical trial studies the following conditions: Stroke.
What interventions are being tested in trial NCT03379532?
The interventions under investigation include: BCI-NMES (DEVICE), Sham-NMES (DEVICE).
Who is sponsoring clinical trial NCT03379532?
This trial is sponsored by University Hospital, Geneva, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03379532 being conducted?
This trial has 2 study locations across Texas, Canton of Geneva. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03379532's enrollment target sits among peer trials
31 300th of 454 higher than 155 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tracking a Tactile Signal Along the Nervous System
RECRUITING · NA
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Strategy Training for Individuals With Unilateral Neglect
RECRUITING · NA
-
Weight Loss and ExeRcise
RECRUITING · NA
-
Safety and Feasibility of an ExoNET for Supination Assistance for Stroke Survivors
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI